Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Liverani C
Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,
Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,
Introduction: Somatostatin receptor (SSTR) overexpression is a unique feature of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which establish the basis for both diagnosis and therapy. SSTR status can be evaluated by immunohistochemical staining (IHC) and 68Ga-DOTATATE PET/CT.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Yu J
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Milione M
Authors: Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L,
Keywords: Gastro-entero-pancreatic neuroendocrine neoplasms, primary tumor, metastasis, Ki-67, mitoses, tumor deposits, clinical outcomes,
Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rinzivillo M
Authors: De Felice I, Rinzivillo M, Pratesi M, Magi L, Annibale B,
Keywords: Pancreatic Exocrine Insufficiency,
Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rossi R
Authors: Rossi R, Altomare M, Monteleone M, Prinzi N, Pusceddu S,
Keywords: radical surgery, recurrence, gastro-entero-pancreatic neuroendocrine neoplasms, prognostic factors,